401 related articles for article (PubMed ID: 12118339)
61. Loss of heterozygosity of TP53 is not correlated with clinicopathological variables in sporadic colorectal carcinomas.
González-Aguilera JJ; Herrero MP; Maillo C; Moreno-Azcoita M; Fernández-Peralta AM
Anticancer Res; 1999; 19(2A):1325-9. PubMed ID: 10368694
[TBL] [Abstract][Full Text] [Related]
62. Interest of investigating p53 status in breast cancer by four different methods.
Thirion A; Rouanet P; Thezenas S; Detournay D; Grenier J; Lopez-Crapez E
Oncol Rep; 2002; 9(6):1167-72. PubMed ID: 12375013
[TBL] [Abstract][Full Text] [Related]
63. Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study.
Havrilesky L; Darcy kM; Hamdan H; Priore RL; Leon J; Bell J; Berchuck A;
J Clin Oncol; 2003 Oct; 21(20):3814-25. PubMed ID: 14551300
[TBL] [Abstract][Full Text] [Related]
64. p53 alteration is not an independent prognostic indicator, but affects the efficacy of adjuvant chemotherapy in human pancreatic cancer.
Dong M; Nio Y; Yamasawa K; Toga T; Yue L; Harada T
J Surg Oncol; 2003 Feb; 82(2):111-20. PubMed ID: 12561067
[TBL] [Abstract][Full Text] [Related]
65. Genetic and epigenetic changes in the APC gene in sporadic colorectal carcinoma with synchronous adenoma.
Kim JC; Koo KH; Roh SA; Cho YK; Kim HC; Yu CS; Kim HJ; Kim JS; Cho MK
Int J Colorectal Dis; 2003 May; 18(3):203-9. PubMed ID: 12673484
[TBL] [Abstract][Full Text] [Related]
66. Detection of p53 point mutations in primary human vulvar cancer by PCR and temperature gradient gel electrophoresis.
Sliutz G; Schmidt W; Tempfer C; Speiser P; Gitsch G; Eder S; Schneeberger C; Kainz C; Zeillinger R
Gynecol Oncol; 1997 Jan; 64(1):93-8. PubMed ID: 8995554
[TBL] [Abstract][Full Text] [Related]
67. Generation of loss of heterozygosity and its dependency on p53 status in human lymphoblastoid cells.
Honma M
Environ Mol Mutagen; 2005; 45(2-3):162-76. PubMed ID: 15688360
[TBL] [Abstract][Full Text] [Related]
68. Have p53 gene mutations and protein expression a different biological significance in colorectal cancer?
Bazan V; Migliavacca M; Tubiolo C; Macaluso M; Zanna I; Corsale S; Amato A; Calò V; Dardanoni G; Morello V; La Farina M; Albanese I; Tomasino RM; Gebbia N; Russo A
J Cell Physiol; 2002 May; 191(2):237-46. PubMed ID: 12064467
[TBL] [Abstract][Full Text] [Related]
69. Humoral response to p53 is associated with conserved domains II and IV mutations in human colorectal cancer: a case-control study in Taiwan.
Wu CM; Tang R; Chen JR; Wu MC; Chien HT; Changchien CR; Hsieh LL
Oncol Rep; 2004 Nov; 12(5):1045-51. PubMed ID: 15492791
[TBL] [Abstract][Full Text] [Related]
70. Sensitive detection of p53 mutation: analysis by direct sequencing and multisequence analysis.
Rozemuller EH; Kropveld A; Kreyveld E; Leppers FG; Scheidel KC; Slootweg PJ; Tilanus MG
Cancer Detect Prev; 2001; 25(2):109-16. PubMed ID: 11341345
[TBL] [Abstract][Full Text] [Related]
71. [p53 mutations and protein overexpression in primary colorectal cancer and its liver metastasis].
Yang Y; Xia Q; Lian F
Zhonghua Zhong Liu Za Zhi; 1999 Mar; 21(2):114-8. PubMed ID: 11776850
[TBL] [Abstract][Full Text] [Related]
72. P53 mutations in primary and metastatic tumors and circulating tumor cells from colorectal carcinoma patients.
Khan ZA; Jonas SK; Le-Marer N; Patel H; Wharton RQ; Tarragona A; Ivison A; Allen-Mersh TG
Clin Cancer Res; 2000 Sep; 6(9):3499-504. PubMed ID: 10999735
[TBL] [Abstract][Full Text] [Related]
73. [p53 gene point mutation in human colorectal carcinoma].
Xu W; Yang D; Wan Y
Zhonghua Zhong Liu Za Zhi; 1995 Sep; 17(5):328-31. PubMed ID: 8697967
[TBL] [Abstract][Full Text] [Related]
74. Inverse correlation between RER+ status and p53 mutation in colorectal cancer cell lines.
Cottu PH; Muzeau F; Estreicher A; Fléjou JF; Iggo R; Thomas G; Hamelin R
Oncogene; 1996 Dec; 13(12):2727-30. PubMed ID: 9000147
[TBL] [Abstract][Full Text] [Related]
75. Mutations in the p53 and Ki-ras genes, microsatellite instability and site of tumor origin in colorectal cancer.
Catalano T; Curia MC; Aceto G; Verginelli F; Cascinu S; Cama A; Mariani-Costantini R; Teti D; Battista P
Oncol Rep; 2005 Sep; 14(3):625-31. PubMed ID: 16077965
[TBL] [Abstract][Full Text] [Related]
76. Analysis of somatic molecular changes, clinicopathological features, family history, and germline mutations in colorectal cancer families: evidence for efficient diagnosis of HNPCC and for the existence of distinct groups of non-HNPCC families.
Johnson V; Lipton LR; Cummings C; Eftekhar Sadat AT; Izatt L; Hodgson SV; Talbot IC; Thomas HJ; Silver AJ; Tomlinson IP
J Med Genet; 2005 Oct; 42(10):756-62. PubMed ID: 15788729
[TBL] [Abstract][Full Text] [Related]
77. Infrequent mutation of the p53 gene in fibrous tumors of infancy and childhood.
Boman F; Peters J; Ragge N; Triche T
Diagn Mol Pathol; 1993 Mar; 2(1):14-22. PubMed ID: 8287221
[TBL] [Abstract][Full Text] [Related]
78. Mutational analysis of the p73 gene localized at chromosome 1p36.3 in colorectal carcinomas.
Sunahara M; Ichimiya S; Nimura Y; Takada N; Sakiyama S; Sato Y; Todo S; Adachi W; Amano J; Nakagawara A
Int J Oncol; 1998 Aug; 13(2):319-23. PubMed ID: 9664127
[TBL] [Abstract][Full Text] [Related]
79. Epidemiological study of p53 tumor suppressor gene mutations in patients from Luxembourg and the German Saar region with an advanced colorectal cancer using PCR-SSCP analysis.
Pauly M; Schmitz M; Kayser I; Lagoda P; Türeci O; Kerschen A; Weber J; Seitz G; Hentges F; Dicato M
Biomed Pharmacother; 1998; 52(5):220-8. PubMed ID: 9755819
[TBL] [Abstract][Full Text] [Related]
80. P53 mutations in colorectal cancer from northern Iran: Relationships with site of tumor origin, microsatellite instability and K-ras mutations.
Mahdavinia M; Bishehsari F; Verginelli F; Cumashi A; Lattanzio R; Sotoudeh M; Ansari R; Semeraro D; Hormazdi M; Fakheri H; Rakhshani N; De Lellis L; Curia MC; Cama A; Piantelli M; Malekzadeh R; Iacobelli S; Mariani-Costantini R
J Cell Physiol; 2008 Aug; 216(2):543-50. PubMed ID: 18330889
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
